A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)

Active, not recruiting · Phase 3 · NCT06491914

Conditions: Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema

Research payments reported, 2025: $37.3M
U.S. investigators named: 60
Sites paid: 53
Planned or actual enrollment: 1,126

About the trial

Sponsor: Regeneron Pharmaceuticals
Tested: Aflibercept 8 mg (drug)
Dates: Started 2024-07-24; completion 2027-01-07
Results posted: Yes

This study is researching aflibercept high dose (HD), referred to as "study drug", with an experimental dosing regimen. The study is focused on participants with nAMD and DME that have been previously treated with anti-vascular endothelial growth factor (anti-VEGF) medications. The aim of the study is to see how safe and effective aflibercept HD injections are when given as frequently as every 4 weeks. The study is also looking at what side effects may happen from taking the study drug.

From ClinicalTrials.gov, last updated 2026-09-18. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Regeneron Pharmaceuticals, Inc. reported $37.3M in research payments for this study in 2025 (20,562 payments).

Products named: Eylea Hd

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Retina Consultants of Texas $6.5M
Cumberland Valley Retina Consultants PC $2.3M
Retina Associates PC $2.0M
Austin Retina Associates $1.7M
Tennessee Retina PC $1.7M
Mid Atlantic Retina Specialists $1.6M
Pautler Cohen Findlay and Eichenbaum MDs PA $1.6M
Long Island Vitreoretinal Consultants $1.4M
Retina Group of New England PC $1.3M
Retina Consultants of Southern Colorado PC $1.3M
University Retina and Macula Associates PC $1.2M
Florida Retina Institute $1.1M
California Eye Specialists Medical Group Inc $1.1M
Palmetto Retina Center LLC $922,531
Illinois Retina Associates PLLC $806,175
Retina Consultants of Southern California Medical Associates Inc $772,930
Charleston Neuroscience Institute LLC $742,063
California Retina Consultants $663,359
Advanced Research $600,166
Eyehealth Northwest PC $580,882
Retina Research Institute of Texas $567,302
Retina Associates of Cleveland Inc $515,030
Win Retina $483,927
Retinal Consultants Medical Group Inc $482,091
Vitreoretinal Surgery PLLC $461,552
Eye Associates of New Mexico LTD $399,420
Eye Associates of Pinellas $378,347
Retina Consultants of Hawaii Research Account $335,344
Mid Atlantic Retina $335,103
Salehi Retina Institute $318,552
Ophthalmic Consultants of Boston $309,174
Deep Blue Retina Clinical Research PLLC $302,798
Advanced Vision Research Institute $297,072
Pacific Northwest Retina $255,325
Retina Group Inc $240,765
Carson Mcbeath and Boswell Inc $228,027
Michael Javaheri MD Inc $173,034
Vision Research Institute LLC $166,884
Florida Retina Consultants $165,169
Retina Specialty Institute $153,661
Texas Retina Associates $141,004
Emanuelli Research and Development Center LLC $136,086
Cincinnati Eye Institute $105,283
Georgia Retina P C $78,911
Visionaire Products Inc $68,438
Vitreous and Retina Consultants PA $66,917
Tulsa Retina Consultants PLLC $36,762
Total Practice Management $26,551
Javaheri Michael MD Inc $21,749
$16,318
Cleveland Clinic, OH $10,500
Pittsburgh Research Institute LLC $9,017
Northern California Retina Vitreous Association $5,000
Springfield Clinic LLP $4,250

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.

At a glance

About the trial

Industry funding

U.S. investigators named on this study

Sites paid to run it